Statins and oxidative stress in the cardiovascular system
Statins are widely established as an important class of medications for primary and secondary prevention of cardiovascular disease. In addition to their lipid-lowering effects, mounting evidence suggests that statins exhibit non-lipid-lowering mediated effects in the cardiovascular system. These so...
| 主要な著者: | , , |
|---|---|
| フォーマット: | Journal article |
| 出版事項: |
Bentham Science Publishers
2017
|
| _version_ | 1826290069327052800 |
|---|---|
| author | Margaritis, M Sanna, F Antoniades, C |
| author_facet | Margaritis, M Sanna, F Antoniades, C |
| author_sort | Margaritis, M |
| collection | OXFORD |
| description | Statins are widely established as an important class of medications for primary and secondary prevention of cardiovascular disease. In addition to their lipid-lowering effects, mounting evidence suggests that statins exhibit non-lipid-lowering mediated effects in the cardiovascular system. These so called “pleiotropic” effects are partly due to antioxidant properties of statins. These are mediated by inhibition of the mevalonate pathway, which interferes with small GTP-ase protein prenylation. This, in turn, leads to anti-oxidant effects of statins via a plethora of mechanisms. Statins prevent the activation of the pro-oxidant enzyme NADPH-oxidase by interfering with Rac1 activation and translocation to the membrane, as well as reducing expression of crucial subunits of NADPH-oxidase. Statins also enhancing the expression, enzymatic activity and coupling of endothelial nitric oxide synthase (eNOS), through mevalonate-dependent effects. The net result is a restoration of the redox balance in the cardiovascular system, with subsequent anti-atherosclerotic and cardioprotective effects. While the evidence from basic science studies and animal models is strong, more clinical trials are required to establish the relevance of these pleiotropic effects to human cardiovascular disease and potentially lead to expanded indications for statin treatment or alternative therapeutic strategies. |
| first_indexed | 2024-03-07T02:38:33Z |
| format | Journal article |
| id | oxford-uuid:a9a49e4b-66e5-42a4-ab73-e39a2ba0d73e |
| institution | University of Oxford |
| last_indexed | 2024-03-07T02:38:33Z |
| publishDate | 2017 |
| publisher | Bentham Science Publishers |
| record_format | dspace |
| spelling | oxford-uuid:a9a49e4b-66e5-42a4-ab73-e39a2ba0d73e2022-03-27T03:09:47ZStatins and oxidative stress in the cardiovascular systemJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:a9a49e4b-66e5-42a4-ab73-e39a2ba0d73eSymplectic Elements at OxfordBentham Science Publishers2017Margaritis, MSanna, FAntoniades, CStatins are widely established as an important class of medications for primary and secondary prevention of cardiovascular disease. In addition to their lipid-lowering effects, mounting evidence suggests that statins exhibit non-lipid-lowering mediated effects in the cardiovascular system. These so called “pleiotropic” effects are partly due to antioxidant properties of statins. These are mediated by inhibition of the mevalonate pathway, which interferes with small GTP-ase protein prenylation. This, in turn, leads to anti-oxidant effects of statins via a plethora of mechanisms. Statins prevent the activation of the pro-oxidant enzyme NADPH-oxidase by interfering with Rac1 activation and translocation to the membrane, as well as reducing expression of crucial subunits of NADPH-oxidase. Statins also enhancing the expression, enzymatic activity and coupling of endothelial nitric oxide synthase (eNOS), through mevalonate-dependent effects. The net result is a restoration of the redox balance in the cardiovascular system, with subsequent anti-atherosclerotic and cardioprotective effects. While the evidence from basic science studies and animal models is strong, more clinical trials are required to establish the relevance of these pleiotropic effects to human cardiovascular disease and potentially lead to expanded indications for statin treatment or alternative therapeutic strategies. |
| spellingShingle | Margaritis, M Sanna, F Antoniades, C Statins and oxidative stress in the cardiovascular system |
| title | Statins and oxidative stress in the cardiovascular system |
| title_full | Statins and oxidative stress in the cardiovascular system |
| title_fullStr | Statins and oxidative stress in the cardiovascular system |
| title_full_unstemmed | Statins and oxidative stress in the cardiovascular system |
| title_short | Statins and oxidative stress in the cardiovascular system |
| title_sort | statins and oxidative stress in the cardiovascular system |
| work_keys_str_mv | AT margaritism statinsandoxidativestressinthecardiovascularsystem AT sannaf statinsandoxidativestressinthecardiovascularsystem AT antoniadesc statinsandoxidativestressinthecardiovascularsystem |